United Therapeutics (NASDAQ:UTHR) CFO Sells $5,359,000.00 in Stock

Key Points

• James Edgemond, United Therapeutics' CFO, sold 10,000 shares on March 26 at an average of $535.90 for $5,359,000 (and had sold 10,000 shares on March 23 at ~$527.48), reducing his stake by 34.63% to 18,876 shares valued at about $10.12M—totaling roughly $10.63M from both recent sales.
• United Therapeutics beat quarterly EPS expectations ($7.70 vs. $6.78) while slightly missing revenue, has a market cap of about $22.9B, and carries a consensus Moderate Buy rating with an average target near $549.91 as several analysts raised targets into the $600–$705 range.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the business's stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $535.90, for a total transaction of $5,359,000.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company's stock, valued at approximately $10,115,648.40. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

James Edgemond also recently made the following trade(s):

• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Stock Performance

UTHR opened at $522.83 on Friday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $549.50. The stock has a market capitalization of $22.92 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84. The business's 50-day simple moving average is $495.95 and its 200-day simple moving average is $472.65.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analysts' expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business's revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm earned $6.19 EPS. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the topic of a number of research reports. Bank of America restated a "neutral" rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. HC Wainwright raised their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Finally, UBS Group lifted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $549.91.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. grew its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares during the last quarter. Creative Planning increased its stake in United Therapeutics by 10.1% in the 2nd quarter. Creative Planning now owns 4,270 shares of the biotechnology company's stock valued at $1,227,000 after buying an additional 392 shares during the period. MAI Capital Management raised its position in United Therapeutics by 16.5% during the 2nd quarter. MAI Capital Management now owns 572 shares of the biotechnology company's stock worth $164,000 after buying an additional 81 shares during the last quarter. XTX Topco Ltd lifted its stake in shares of United Therapeutics by 377.5% in the 2nd quarter. XTX Topco Ltd now owns 4,851 shares of the biotechnology company's stock worth $1,394,000 after acquiring an additional 3,835 shares during the period. Finally, Advisors Asset Management Inc. lifted its stake in shares of United Therapeutics by 3.1% in the 2nd quarter. Advisors Asset Management Inc. now owns 4,013 shares of the biotechnology company's stock worth $1,153,000 after acquiring an additional 121 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.